Reported Earlier, Estrella’s EB103 Dosed Twice Three Weeks Apart In First Dose-Expansion Patient At Recommended Phase II Dose, No Treatment-Related SAEs; Dose-Escalation Delivered 100% Month 1 Complete Response In High-Dose Cohort - Son Haberler